Cellular Biomedicine’s drug application for ReJoin® therapy for knee osteoarthritis (KOA) has been accepted for a Phase II clinical trial in China.
ReJoin is an off-the-shelf autologous mesenchymal progenitor cell therapy, developed completely in-house. It comprises adipose tissue obtained from the patient that is expanded using a serum- and antibiotics-free culture medium, which is then formulated for ReJoin.
This marks the company’s second clinical trial accepted in China for stem cells this year, following a trial of AlloJoin® allogenic therapy for the same application. That trial launched earlier this month.
“We are very pleased to have our second stem cell therapy accepted for a Phase II trial,” said Tony Liu, CEO. “ReJoin showed promise for the prevention of cartilage deterioration in knee osteoarthritis in our Phase I study. Our team is dedicated to researching potential options for the millions of people who suffer from knee osteoarthritis.”
Mr. Liu added, “Conducting parallel autologous and allogenic clinical trials will allow us to cover the spectrum in stem cell research for KOA and will bring us closer to helping address the unmet medical needs of KOA patients in China.”
Autologous cell therapy products are manufactured from the patient’s own tissue, while allogeneic products are donor-derived.
Cellular Biomedicine's drug application for ReJoin® therapy for knee osteoarthritis (KOA) has been accepted for a Phase II clinical trial in China.
ReJoin is an off-the-shelf autologous mesenchymal progenitor cell therapy, developed completely in-house. It comprises adipose tissue obtained from the patient that is expanded using a serum- and...
Cellular Biomedicine’s drug application for ReJoin® therapy for knee osteoarthritis (KOA) has been accepted for a Phase II clinical trial in China.
ReJoin is an off-the-shelf autologous mesenchymal progenitor cell therapy, developed completely in-house. It comprises adipose tissue obtained from the patient that is expanded using a serum- and antibiotics-free culture medium, which is then formulated for ReJoin.
This marks the company’s second clinical trial accepted in China for stem cells this year, following a trial of AlloJoin® allogenic therapy for the same application. That trial launched earlier this month.
“We are very pleased to have our second stem cell therapy accepted for a Phase II trial,” said Tony Liu, CEO. “ReJoin showed promise for the prevention of cartilage deterioration in knee osteoarthritis in our Phase I study. Our team is dedicated to researching potential options for the millions of people who suffer from knee osteoarthritis.”
Mr. Liu added, “Conducting parallel autologous and allogenic clinical trials will allow us to cover the spectrum in stem cell research for KOA and will bring us closer to helping address the unmet medical needs of KOA patients in China.”
Autologous cell therapy products are manufactured from the patient’s own tissue, while allogeneic products are donor-derived.
Copy to clipboard 
